Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

Novartis Chief Digital Officer, Bertrand Bodson, and Microsoft Corporate Vice President Research & Incubation, Peter Lee, discussed why healthcare’s digital moment is now.

The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.

NIBR translational immunologists and academic colleagues observe two distinct molecular patterns of disease progression in lung tissue samples.

To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps everyone be inspired to innovate every day.

Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.

Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.

Learn how we are shifting from making the patient fit the treatment to making the treatment fit the patient.